ZYDELIG® dosing

1 pill, twice daily

ZYDELIG offers convenient oral dosing

150 mg po BID

Recommended starting dose

Image of ZYDELIG® (idelalisib) 150 mg tablets bottle.

100 mg po BID

Available for managing select AEs

Image of ZYDELIG® (idelalisib) 100 mg tablets bottle.

Pill images and bottles are not actual size.

Taking ZYDELIG

  • Tablets should be swallowed whole. ZYDELIG can be taken with or without food
  • Continue treatment until disease progression or unacceptable toxicity
  • No dose adjustment of ZYDELIG is necessary for patients with CrCl ≥15 mL/min 2
  • No dose modification is required for lymphocytosis, which has been observed in some patients taking ZYDELIG. This observed lymphocytosis is a pharmacodynamic effect and should not be considered progressive disease in the absence of other clinical findings

Provide PJP prophylaxis during treatment with ZYDELIG

  • Serious or fatal PJP or CMV occurred in <1% of patients treated with ZYDELIG

View additional details and clinical trials experience with 100 mg dose

Go to adverse event monitoring & management

Image of dosing guide

Dosing guide

Download PDF

Efficacy in relapsed
follicular lymphoma

Learn more

Adverse event monitoring &
management

Learn more

ZYDELIG®
Access Connect®

Learn more

AE=adverse event; BID=twice daily; CMV=cytomegalovirus; CrCl=creatinine clearance; PJP=Pneumocystis jirovecii pneumonia; po=orally.

References:

  1. ZYDELIG® (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; rev January 2018.
  2. Jin F, Robeson M, Zhou H, Hisoire G, Ramanathan S. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Cancer Chemother Pharmacol. 2015;76(6):1133-1141.